ATR (ATM and Rad3-related) encodes a phosphatidylinositol 3-kinase-like serine/threonine kinase that is a central coordinator of replication stress responses and genome maintenance[1][2]. In dividing cells, ATR stabilizes stalled replication forks, activates checkpoint signaling (especially CHK1), and prevents premature mitotic entry under DNA stress. In nervous system biology, ATR signaling is relevant not only during development and progenitor expansion, but also in post-mitotic neurons where DNA damage and aberrant cell-cycle signaling can contribute to degeneration.
Within NeuroWiki disease models, ATR sits at the intersection of DNA damage response, neuroinflammation-linked oxidative injury, and selective neuronal vulnerability in disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
ATR belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) family, which includes ATM, DNA-PKcs, and mTOR[1:1]. The ATR protein contains several key structural domains:
Unlike ATM, which is activated primarily by double-strand breaks, ATR responds to a broader spectrum of replication-associated lesions including single-stranded DNA gaps, stalled forks, and nucleotide depletion[2:1].
The functional unit of ATR signaling is the ATR-ATRIP complex. ATRIP (ATR-interacting protein) serves as the primary ssDNA sensor through its binding to replication protein A (RPA)[1:2][2:2]. This recruitment mechanism allows ATR to localize specifically to sites of replication stress rather than throughout the genome.
Key interactions within the ATR-ATRIP complex include:
Once activated, ATR phosphorylates numerous substrates that orchestrate cellular responses:
| Substrate | Function | Neurodegeneration Relevance |
|---|---|---|
| CHK1 | Checkpoint enforcement, cell cycle arrest | Cell cycle re-entry in AD neurons |
| RPA2 | Replication fork stabilization | DNA damage accumulation |
| p53 | Transcription regulation, apoptosis | Neuronal death pathways |
| FANCE | Fanconi anemia pathway | Crosslink repair deficiency |
| SMARCAL1 | Fork remodeling | Replication stress response |
Rapidly proliferating neural progenitors are highly sensitive to replication stress. Experimental ATR pathway disruption in developmental contexts can trigger progenitor apoptosis, tissue disorganization, and long-term neuronal deficits[3][4]. These findings support a model in which ATR signaling is required to complete neurodevelopment under endogenous replication stress load.
During cortical neurogenesis, ATR deficiency leads to:
These developmental findings have implications for understanding prenatal risk factors and developmental origins of neurodegeneration[3:1].
Neurons do not replicate DNA, but they accumulate diverse DNA lesions over long lifespans and can activate stress-checkpoint networks in response to oxidative and metabolic injury. Emerging work indicates ATR signaling can modulate neuronal excitability and synaptic output under stress states, suggesting non-canonical neuronal roles beyond classical S-phase checkpoint biology[5].
Key observations in post-mitotic neurons include:
AD pathology includes oxidative stress, mitochondrial dysfunction, and genomic instability signatures. Replication-stress-like signaling and cell-cycle re-entry phenotypes are observed in vulnerable neurons in multiple models. ATR-linked pathways are therefore relevant as part of broader DNA damage response remodeling in AD[6][7].
Specific mechanisms linking ATR to AD:
In dopaminergic systems, mitochondrial redox burden and catecholamine-derived stress can elevate DNA damage signaling. ATR is not currently a frontline monogenic PD driver, but ATR pathway competence likely modifies neuronal resilience under chronic genotoxic stress environments[8].
PD-specific considerations:
Motor neurons show cumulative DNA damage burden and impaired proteostasis in several ALS subtypes. ATR pathway activation is one component of this stress landscape, potentially adaptive early and maladaptive when chronic or dysregulated[9].
ALS-ATR connections:
ATR signaling participates in the broader DNA damage response landscape in Huntington's disease. Mutant huntingtin protein impairs DNA repair capacity, potentially overwhelming ATR-dependent checkpoint functions.
In multiple system atrophy, oligodendrocytic dysfunction includes impaired DNA repair mechanisms. ATR pathway competence in glial cells may influence disease progression.
ATR interacts with numerous proteins that modulate its activity and substrate access:
The PIKK family coordinates cellular responses to genotoxic stress:
ATR has strong oncology visibility due to ATR inhibitors; however, neurodegeneration translational logic is different. For neurodegeneration, indiscriminate ATR inhibition is unlikely to be beneficial because baseline genome maintenance is protective in long-lived cells. Higher-value directions include[10][11]:
Key experimental question: when does ATR signaling represent adaptive protection versus a contributor to pathological cell-state transitions?
| Compound | Mechanism | Stage | Notes |
|---|---|---|---|
| VE-822 (VX-970) | ATR inhibitor | Preclinical/Phase 1 | Oncology-focused |
| AZD6738 | ATR inhibitor | Phase 1/2 | Radiosensitizer |
| ETP-46464 | ATR inhibitor | Preclinical | |
| Caffeine | ATM/ATR inhibitor | Historical | Non-selective |
Note: These compounds are primarily developed for cancer therapy. Neurodegeneration applications would require different dosing and timing strategies.
Actionable biomarker concepts for ATR-axis studies include[12]:
These biomarkers are most useful in mechanism-driven early-phase trials rather than broad, unstratified cohorts.
GWAS studies have identified variants in DNA damage response genes that modify neurodegenerative disease risk. While direct ATR variants in AD/PD are not strongly implicated, pathway-level effects are under investigation.
Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008. ↩︎ ↩︎ ↩︎
Flynn RL, Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci. 2011. ↩︎ ↩︎ ↩︎
McKinnon PJ. Protective Mechanisms Against DNA Replication Stress in the Nervous System. Genes Dev. 2020. ↩︎ ↩︎
de Klein A, et al. Progenitor death drives retinal dysplasia and neuronal degeneration in a mouse model of ATRIP-Seckel syndrome. PLoS Genet. 2020. ↩︎
Cressant A, et al. ATR regulates neuronal activity by modulating presynaptic firing. Cell Rep. 2021. ↩︎
Suberbielle E, et al. Molecular Connections between DNA Replication and Cell Death in beta-Amyloid-Treated Neurons. Cell Death Discov. 2023. ↩︎
Wang W, et al. DNA Damage and Repair in Alzheimer's Disease: New Perspectives and Potential Therapeutic Targets. J Alzheimers Dis. 2023. ↩︎
Gonzalez-Hunt CP, et al. DNA damage by oxidative stress in Parkinson's disease. J Neurosci Res. 2022. ↩︎
Walker C, et al. DNA damage and repair in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021. ↩︎
Rundle S, et al. Targeting the DNA damage response in cancer therapy. Nat Rev Cancer. 2018. ↩︎
Kwok M, et al. ATR inhibitors as a synthetic lethal therapy for ATM-deficient cancers. Leukemia. 2016. ↩︎
Barzilai A, et al. DNA damage response biomarkers in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2023. ↩︎